"A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"
1509-0003
Phase 1 other active
Quick answer
"A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies" for Type 1 interferonopathies is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Type 1 interferonopathies
- Phase
- Phase 1
- Modality
- other
- Status
- active